Ad Header



The Pulse of the Pharmaceutical Industry

  • Filter By Category

  • Filter By Author

Bystander defibrillator use tied to better cardiac arrest outcomes

Cardiac arrest patients may be more likely to survive and avoid permanent disabilities when bystanders use a defibrillator to treat them before an ambulance arrives, a new study suggests.

Read More »

Price of Teva’s Generic Drug to Treat Wilson’s Disease Sparks Outrage

Wilson’s disease patients had been champing at the bit for Teva’s generic version of Syprine that the company called a “lower-cost generic.” But after the drug launched in February 2018, patients discovered that Teva’s generic is not eally that much cheaper than Valeant Pharmaceuticals International’s branded drug.

Read More »

ObsEva Fertility Drug Shows Some Promise in Late-Stage Trial

Shares of ObsEva climbed after the company highlighted a data point from a late-stage trial that showed its fertility treatment nolasiban was successful in improving the pregnancy rate of some women following in vitro fertilization.

Read More »

Trulicity Combo Shows Improved Blood Sugar Control

Eli Lilly published results from a new Phase IIIb study of Trulicity (dulaglutide) in combination with a SGLT-2 inhibitor showing improved blood sugar control in adults with type 2 diabetes.

Read More »

Shares Plunge as ARCA biopharma’s Gencaro has Mixed Phase II Clinical Trial Results

ARCA biopharma, based in Westminster, Colorado, announced results from its Phase IIb clinical trial of Gencaro (bucindolol hydrochloride) in patients with atrial fibrillation.

Read More »

U.S. patent court deals setback to Allergan’s Restasis strategy

A U.S. administrative court said it has the authority to decide the validity of patents Allergan transferred to a Native American tribe.

Read More »

Vodafone’s mobile data to be deployed to fight epidemics in Ghana

Mobile data will be used in Ghana to track and control epidemics, helping prevent a repeat of the 2014 West Africa Ebola outbreak, in a pioneering program announced by Vodafone Foundation.

Read More »

KemPharm’s opioid painkiller gets FDA approval

KemPharm Inc. said the U.S. Food and Drug Administration approved the drugmaker’s opioid painkiller Apadaz for the short-term management of acute pain.

Read More »

Teva’s Shrinking U.S. Footprint

Teva Pharmaceuticals Inc. made more cuts in the United States, this time to real estate holdings. To save money, the company will close its offices in Washington, D.C. and New York City. No jobs were reported to be lost from the cuts.

Read More »

Tax Reform Could Lead to Spike in Biopharma M&A Activity

The passing of tax reform led most analysts to predict that 2018 will be a strong year for mergers and acquisitions. Yet, despite what appears like a good start to the year, not all companies are jumping immediately on the M&A bandwagon.

Read More »

Ad Right Top


Extensive pharmaceutical business and marketing intelligence. For back issues, please contact

April 2019 Focus: Healthcare agency & network profiles, industry overview & awards, and more!


Ad Right Bottom